In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mirna Therapeutics Inc.

Division of Synlogic Inc.
www.mirnatherapeutics.com

Latest From Mirna Therapeutics Inc.

Synlogic Moves Synthetic Biotics To The Clinic For Rare Metabolic Disease

Emerging Company Profile: Pioneering the development of a new class of living medicines that work in the microbiome, Synlogic completed a reverse merger earlier this year that took the company public.

StartUps and SMEs Metabolic Disorders

IPO Update: New Filings Feed Investor Fervor As Biopharma Stocks Rise

IPO launches in the US hit a wall in August, but several biopharma firms recently entered the queue, adding new opportunities for investors to chase the industry's outperforming returns.

Business Strategies Financing

Start-Up Quarterly Statistics: Private And Public Firms Were Prolific Fundraisers

A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.

StartUps and SMEs Financing

Deal Watch: Takeda Signs Broad Cancer Collaboration With Nektar

Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijin.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Synlogic Inc.
  • Senior Management
  • Paul Lammers, MD, Pres. & CEO
    Miguel Barbosa, PhD, CSO
    Casi DeYoung, CBO
  • Contact Info
  • Mirna Therapeutics Inc.
    Phone: (512) 901-0900
    2150 Woodward St.
    Ste. 100
    Austin, TX 78744
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register